Catecholamine biosynthetic enzyme

Catecholamine biosynthetic enzymes are a group of enzymes responsible for the stepwise conversion of the amino acid tyrosine into the major catecholamines—dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). The canonical pathway involves four key enzymes: 1. **Tyrosine hydroxylase** catalyzes the rate-limiting step by converting tyrosine to L-DOPA. 2. **Aromatic L-amino acid decarboxylase** converts L-DOPA to dopamine. 3. **Dopamine beta-hydroxylase** converts dopamine to norepinephrine. 4. **Phenylethanolamine N-methyltransferase** converts norepinephrine to epinephrine. These enzymes are highly regulated at multiple levels including feedback inhibition by their products and phosphorylation-dependent modulation. They play essential roles in neurotransmission within both central and peripheral nervous systems as well as in hormonal responses mediated by the adrenal medulla during stress ("fight-or-flight" response)[1][2][4][7]. Mutations or dysregulation in these enzymes are implicated in various diseases such as Parkinson’s disease, schizophrenia, cardiovascular disorders, and certain metabolic syndromes. The term "catecholamine biosynthetic enzymes" is not a single molecular target but rather refers collectively to this family of related but distinct enzymatic proteins; therefore it is too broad for precise drug targeting without specifying an individual enzyme such as "tyrosine hydroxylase"[1][4].

Other names

Tyrosine hydroxylase (TH)Aromatic L-amino acid decarboxylase (AADC, DDC)Dopamine beta-hydroxylase (DBH)Phenylethanolamine N-methyltransferase (PNMT)

Inhibition of tyrosine hydroxylase to reduce catecholamine synthesis[3]; Supplementation with L-DOPA to increase dopamine levels in Parkinson’s disease[7]